TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating ...
MarketBeat on MSN7h
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Jumbo targets a payout ratio of 65%-85% of statutory net profit after tax. We see payouts at the top of this range as appropriate, given the resilience of earnings and the cash-generative, ...
Narrow-moat-rated Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback